Enhancing Immunotherapy Potential Through PD-L1 Upregulation—Combination of Anti-PD-L1 and mTOR Inhibitors Background Introduction In recent years, immune checkpoint inhibitors (ICIs) have made significant progress in cancer treatment, particularly in the treatment of urothelial cancer (UC). PD-1/PD-L1 inhibitors restore T cell anti-tumor activity ...

Multi-Cancer Detection Using Multiplex Droplet Digital PCR Methylation Assay Background Cancer is one of the leading causes of death worldwide, with nearly 10 million deaths reported in 2020. Although many cancers can be cured when detected and treated early, many patients are still diagnosed at advanced stages, leading to poor treatment outcomes. ...

Dynamic Changes in Estrogen Receptor Alpha (ERα) Promoter Methylation and Drug Resistance in Breast Cancer Cells Background Breast cancer is one of the most common cancers among women worldwide, with approximately 75% of breast cancer patients expressing estrogen receptor alpha (ERα, gene symbol ESR1). ERα is not only an important prognostic marker...

Immunogenicity and Therapeutic Challenges of IDH-Mutant Gliomas Background Glioma is a common central nervous system tumor, and its treatment and prognosis vary significantly depending on molecular characteristics. In recent years, the diagnostic and prognostic significance of isocitrate dehydrogenase (IDH) mutations in gliomas has been increasingl...

The Role of SRSF10 in Immunotherapy for Hepatocellular Carcinoma Academic Background Hepatocellular carcinoma (HCC) ranks sixth in global cancer incidence and third in mortality. Although surgical resection is the primary treatment for HCC, the high postoperative recurrence rate significantly impacts patient prognosis. In recent years, immunotherap...